ExploreWatchlistsPricing
  1. JP-listed companies
  2. Astellas Pharma Inc.
  3. Financials
  4. Total assets

Astellas Pharma Inc. (4503)

Market cap
¥4.62T
P/E ratio
18.3x
Astellas Pharma develops, manufactures, and sells pharmaceutical products globally through a network of 77 subsidiaries across the US, Europe, and Asia.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal assets (Million JPY)YoY (%)
Mar 31, 20253,339,544-6.44%
Mar 31, 20243,569,603+45.31%
Mar 31, 20232,456,518+5.32%
Mar 31, 20222,332,395+2.58%
Mar 31, 20212,273,628-1.92%
Mar 31, 20202,318,160+22.16%
Mar 31, 20191,897,648+2.12%
Mar 31, 20181,858,205+65.49%
Mar 31, 20171,122,830+1.88%
Mar 31, 20161,102,161+4.69%
Mar 31, 20151,052,782

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat